Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25134153 | 0.94 | SIGMAR1 (0.38) | SIGMAR1KCNJ1KCNH2SLC6A4SLC6A3 | |
| SCHEMBL25133365 | 0.94 | SIGMAR1 (0.38) | SIGMAR1KCNJ1KCNH2SLC6A4SLC6A3 | |
| SCHEMBL25133388 | 0.89 | SIGMAR1 (0.33) | SIGMAR1KCNJ1KCNH2 | |
| SCHEMBL26972455 | 0.88 | SIGMAR1 (0.43) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL25133361 | 0.88 | SIGMAR1 (0.43) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL23919018 | 0.84 | SIGMAR1 (0.37) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL23205219 | 0.84 | SIGMAR1 (0.37) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL23267012 | 0.84 | SIGMAR1 (0.37) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL23875168 | 0.82 | SIGMAR1 (0.39) | SIGMAR1KCNJ1KCNH2KDM1A | |
| SCHEMBL21421602 | 0.82 | KCNH2 (0.34) | KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | SIGMAR1 3941/4885KCNJ1 4286/4885KCNH2 4503/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | SIGMAR1 3941/4885KCNJ1 4286/4885KCNH2 4503/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | SIGMAR1 3038/4885KCNJ1 4742/4885KCNH2 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.